Stock Events

Stock Events

Vicore Pharma AB 

€7.55
10
-€0.05-0.66% 06:03 Today

Statistics

Day High
7.55
Day Low
7.55
52W High
11.88
52W Low
7.55
Volume
-
Avg. Volume
-
Mkt Cap
212.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q1 2026
Q2 2026
Next
-0.04
-0.04
-0.04
-0.03
Expected EPS
-0.0443372
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6Y40.F. It's not an investment recommendation.
Svenska Handelsbanken AB (publ)
4
SHB-A.ST
Aker BP ASA
3
AKRBP.OL
Boliden AB
3
BOL.ST
SED Energy
3
ENH.OL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals is involved in developing therapies for treating cystic fibrosis and other serious diseases, overlapping with Vicore's focus on rare lung disorders.
Incyte
INCY
Mkt Cap23.37B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including treatments for pulmonary diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic disorders that overlap with Vicore's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals is known for its development of treatments for serious medical conditions, including respiratory and inflammatory diseases, competing with Vicore's product pipeline.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences' involvement in pulmonary and fibrotic diseases places it in direct competition with Vicore's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap164.79B
Novo Nordisk is engaged in the discovery and development of biological therapies, including areas that could compete with Vicore's interest in rare diseases.

About

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
Show More
CEO
Ahmed Mousa
Employees
40
Country
Sweden
ISIN
US92581R1041
WKN
000A42DDX

Listings

XNAS
US
VCRE
STU
DE
6Y4.STU
ST
SE
VICO-BTA.ST
F
DE
6Y40.F

0 Comments

Share your thoughts

FAQs

What is Vicore Pharma AB stock price today?▼
The current price of 6Y40.F is €7.55 EUR — it has decreased by -0.66% in the past 24 hours. Watch Vicore Pharma AB stock price performance more closely on the chart.
What is Vicore Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Vicore Pharma AB stocks are traded under the ticker 6Y40.F.
What is Vicore Pharma AB market cap?▼
Today Vicore Pharma AB has the market capitalization of 212.55M
When is the next Vicore Pharma AB earnings date?▼
Vicore Pharma AB is going to release the next earnings report on November 5, 2026.
What were Vicore Pharma AB earnings last quarter?▼
6Y40.F earnings for the last quarter are -0.04 EUR per share, whereas the estimation was -0.04 EUR resulting in a -24.39% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Vicore Pharma AB have?▼
As of October 6, 2026, the company has 40 employees.
In which sector is Vicore Pharma AB located?▼
Vicore Pharma AB operates in the Health & Wellness sector.
When did Vicore Pharma AB complete a stock split?▼
Vicore Pharma AB has not had any recent stock splits.
Where is Vicore Pharma AB headquartered?▼
Vicore Pharma AB is headquartered in Stockholm, Sweden.